Cargando…

Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study

PURPOSE: The purpose of this study is to compare the efficacy of topical cyclosporine (Cs) 0.05% alone and topical Cs 0.05% with loteprednol 0.5% in patients with moderate dry eye. STUDY DESIGN: This was a comparative, prospective, interventional study. PATIENTS AND METHODS: A total of 140 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Singla, Shaveta, Sarkar, Lopamudra, Joshi, Mukesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759554/
https://www.ncbi.nlm.nih.gov/pubmed/31572654
http://dx.doi.org/10.4103/tjo.tjo_15_18
_version_ 1783453714790481920
author Singla, Shaveta
Sarkar, Lopamudra
Joshi, Mukesh
author_facet Singla, Shaveta
Sarkar, Lopamudra
Joshi, Mukesh
author_sort Singla, Shaveta
collection PubMed
description PURPOSE: The purpose of this study is to compare the efficacy of topical cyclosporine (Cs) 0.05% alone and topical Cs 0.05% with loteprednol 0.5% in patients with moderate dry eye. STUDY DESIGN: This was a comparative, prospective, interventional study. PATIENTS AND METHODS: A total of 140 patients diagnosed with moderate dry eyes were randomly divided into two groups. Group A patients received treatment with topical loteprednol 0.5% started as QID dosage for 2 weeks and tapered to BID dosage over the next 6 weeks, topical Cs 0.05% BID and artificial tears. Group B patients received treatment with topical Cs 0.05% BID and artificial tears. All patients were followed over a period of 6 months with ocular surface disease index (OSDI) questionnaire, tear film break up time (TBUT), corneal fluorescein, and lissamine green staining scores. RESULTS: There was a significant difference in the symptoms and signs of dry eye in the group receiving combination of loteprednol 0.5% and Cs 0.05% as compared to the group receiving Cs alone evident by greater reduction in OSDI score, corneal staining, and improvement in TBUT and Schirmer's test values over a follow-up of 6 months. CONCLUSION: Combination therapy with topical loteprednol and Cs is significantly better than topical Cs alone on alleviating symptoms and signs in moderate dry eye patients.
format Online
Article
Text
id pubmed-6759554
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-67595542019-09-30 Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study Singla, Shaveta Sarkar, Lopamudra Joshi, Mukesh Taiwan J Ophthalmol Original Article PURPOSE: The purpose of this study is to compare the efficacy of topical cyclosporine (Cs) 0.05% alone and topical Cs 0.05% with loteprednol 0.5% in patients with moderate dry eye. STUDY DESIGN: This was a comparative, prospective, interventional study. PATIENTS AND METHODS: A total of 140 patients diagnosed with moderate dry eyes were randomly divided into two groups. Group A patients received treatment with topical loteprednol 0.5% started as QID dosage for 2 weeks and tapered to BID dosage over the next 6 weeks, topical Cs 0.05% BID and artificial tears. Group B patients received treatment with topical Cs 0.05% BID and artificial tears. All patients were followed over a period of 6 months with ocular surface disease index (OSDI) questionnaire, tear film break up time (TBUT), corneal fluorescein, and lissamine green staining scores. RESULTS: There was a significant difference in the symptoms and signs of dry eye in the group receiving combination of loteprednol 0.5% and Cs 0.05% as compared to the group receiving Cs alone evident by greater reduction in OSDI score, corneal staining, and improvement in TBUT and Schirmer's test values over a follow-up of 6 months. CONCLUSION: Combination therapy with topical loteprednol and Cs is significantly better than topical Cs alone on alleviating symptoms and signs in moderate dry eye patients. Wolters Kluwer - Medknow 2019-09-12 /pmc/articles/PMC6759554/ /pubmed/31572654 http://dx.doi.org/10.4103/tjo.tjo_15_18 Text en Copyright: © 2019 Taiwan J Ophthalmol http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Singla, Shaveta
Sarkar, Lopamudra
Joshi, Mukesh
Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study
title Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study
title_full Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study
title_fullStr Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study
title_full_unstemmed Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study
title_short Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study
title_sort comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in indian population: a prospective study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759554/
https://www.ncbi.nlm.nih.gov/pubmed/31572654
http://dx.doi.org/10.4103/tjo.tjo_15_18
work_keys_str_mv AT singlashaveta comparisonoftopicalcyclosporinealoneandtopicalloteprednolwithcyclosporineinmoderatedryeyeinindianpopulationaprospectivestudy
AT sarkarlopamudra comparisonoftopicalcyclosporinealoneandtopicalloteprednolwithcyclosporineinmoderatedryeyeinindianpopulationaprospectivestudy
AT joshimukesh comparisonoftopicalcyclosporinealoneandtopicalloteprednolwithcyclosporineinmoderatedryeyeinindianpopulationaprospectivestudy